Design, Synthesis, and Biological Evaluation of BODIPY-Caged Resiquimod as a Dual-Acting Phototherapeutic
Open Access
- 17 February 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (4) , 4561-4581
Abstract
Resiquimod, an imidazoquinoline scaffold, exhibits potent immunotherapeutic activity but is associated with off-target effects, limiting its clinical utility. To address this limitation, we developed a novel BODIPY-caged resiquimod that is responsive to red light, combining photocaging and photodynamic therapy functionalities. Molecular docking studies guided identification of the optimal caging site for resiquimod, effectively masking its immune activity. BODIPY-caged resiquimod remained inactive under dark conditions, effectively masking resiquimod's immunostimulatory effects. However, red light irradiation precisely uncaged resiquimod, inducing robust immune activation, even in the presence of N-acetyl cysteine as an antioxidant. Notably, the attachment of resiquimod to BODIPY reduced the dark toxicity typically associated with BODIPY as a photosensitizer. In 3D spheroid models of HeLa and A549 cells, BODIPY-caged resiquimod demonstrated spatiotemporal control over cytotoxicity, significantly enhancing cell death only upon irradiation. This dual-function therapeutic approach highlights a "win-win" strategy: precise, red-light-mediated control of immune activation and photodynamic efficacy with reduced collateral toxicity.Keywords
Funding Information
- Japan Science and Technology Corporation (JPMJSP2132)
This publication has 50 references indexed in Scilit:
- Rational Design in Photopharmacology with Molecular PhotoswitchesAngewandte Chemie International Edition, 2023
- Role and importance of solvents for the fractionation of lignocellulosic biomassBioresource Technology, 2022
- A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA‐dependent RNA polymerase of wild‐type and Delta subvariant AY.4 of SARS‐CoV‐2Journal of Cellular Biochemistry, 2022
- Supramolecular Self‐Assembly‐Facilitated Aggregation of Tumor‐Specific Transmembrane Receptors for Signaling Activation and Converting Immunologically Cold to Hot TumorsAdvanced Materials, 2021
- Potent Lymphatic Translocation and Spatial Control Over Innate Immune Activation by Polymer–Lipid Amphiphile Conjugates of Small‐Molecule TLR7/8 AgonistsAngewandte Chemie International Edition, 2019
- Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapyActa Biomaterialia, 2019
- Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic studyEuropean Journal of Pharmaceutics and Biopharmaceutics, 2019
- A New Strategy for Fluorogenic Esterase Probes Displaying Low Levels of Non‐specific HydrolysisChemistry – A European Journal, 2015
- Fluorescence Lifetime Spectroscopy and Imaging of Visible Fluorescent Proteins2009
- NF-κB activation by reactive oxygen species: Fifteen years laterBiochemical Pharmacology, 2006